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A Review of Approaches to the Detection of
Genetic Damage in the Human Fetus
by Richard B. Everson*
Studies in experimental animals suggest links between genetic damage to the fetus and the etiology of
several disorders, including fetal loss, teratogenesis, and cancer. Methods for measuring genetic damage
directly in the human fetus could provide epidemiologists and clinical researchers with powerful tools for
investigating similar associations in humans. Current methods potentially available for such studies
include assays for mutagenic substances in human body fluids and for measuring modifications to genetic
material at the three levels of organization of genetic material: the chromosome, the gene or specific
locus, and chemical DNA. Results of studies using fetal tissues to investigate each ofthese end points are
reviewed, emphasizing studies of chemical modifications to DNA nucleotides detected in the human pla-
centa.
Introduction
Damage to fetal genetic material could result in a
number of immediate and long-term effects, including
fetal loss, teratogenesis, germ or somatic cell mutation,
or cancer. Interest in such postnatal effects ofprenatal
exposures was greatly intensified when epidemiologic
studies linked prenatal exposure to diethylstilbestrol
with vaginal cancerin adults, demonstratingthat chem-
ical agents can act as transplacental carcinogens in hu-
mans (1-3). There are, however, few observations in-
dicating that transplacental carcinogenesis occurs in
response to other chemical exposures in the clinical or
epidemiologic literature. Probably the best additional
examples of transplacental induction of cancer by a
chemical are case studies showing that exposure to di-
phenylhydantoin induces neuroblastoma, but the num-
ber of affected children is small (4). More recent epi-
demiologic studies have also suggested associations
between maternal exposure to N-nitroso compounds
and childhood brain tumors (5) and hydrocarbon-related
occupations and childhood leukemia (6), but these stud-
ies require confirmation.
In contrast to the rarity of epidemiologic models for
human transplacental carcinogenesis, there are many
examples of transplacental carcinogenesis in experi-
mental animals (4,7-10). Table 1 reviews several prin-
ciples extracted from this literature. These experimen-
tal studies have shown that exposure offetal tissues to
factors capable ofcausing cancer may be common, and
the studies raise the question: does the clinical and ep-
idemiologic literature lack other examples because
transplacentalcarcinogenesisis notoccurringinhumans
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Table 1. Principles of transplacental carcinogenesis derived
from animal studies.
Prenatal exposure to over 40 chemicals, including most
classes of chemical carcinogens active in postnatal life, can
induce tumors in experimental animals.
Carcinogens (initiators) administered transplacentally can
increase sensitivity to later carcinogenic (initiating or
promoting) exposures.
Many tumors resulting from transplacental exposures occur in
adulthood and at the same sites as spontaneously occurring
tumors.
Compounds present in tobacco smoke and cigarette smoke
condensate are active transplacental carcinogens in animals.
The fetus has greater sensitivity to some carcinogens than
the adult, so that estimates of doses necessary for
transplacental carcinogenesis cannot be accurately
predicted from effects in adults.
or because we do not have the tools to detect transpla-
cental carcinogenesis in humans?
A search for possible exposures that could be used as
models for investigating human transplacental carcin-
ogenesis led to consideration ofcigarette smoking. Ma-
ternal smoking is associated with increased rates for
spontaneous abortion, perinatal mortality, congenital
defects, and low birth weight. Maternal smoking also
causes large increases in some forms ofhumanplacental
metabolism (11). These data indicated that transplacen-
tal exposure to constituents of cigarette smoke occurs
and has biologically important effects. Animal studies
showedthatseveralconstituents ofcigarette smoke and
cigarette smoke condensate itself are transplacental
carcinogens. Taken together, these findings suggested
the possibility thatindividuals transplacentally exposed
to maternal smoking may be at increased cancer risk in
adult life (4). Investigations of this possibility offer an
opportunity both to study this specific hypothesis andR. B. EVERSON
to use these investigations to develop approaches for
similar studies of other exposures.
Using a traditional epidemiologic approach in which
information gathered by questionnaires is linked with
health outcomes from medical records, studies inves-
tigating the effects ofgestational exposure to maternal
smoking were proposed (4) and then piloted (12,13). In
these studies, evaluation ofeffects oftransplacental ex-
posures was complicated by significant associations be-
tween cancer risk and passive exposure to smoking by
the mother or father. They were also hampered by rel-
atively low frequencies ofmaternal use ofcigarettes in
the area in which the studies were conducted. Overall,
in the United States, large numbers of women began
smoking during the 1920s, so that transplacentally ex-
posedindividuals areonlynowreachingtheageatwhich
a high frequency ofcancer would be expected. Despite
these difficulties, a significant association between ma-
ternal smoking and elevated risk of hematopoietic ma-
lignancies was observed [relative risk (RR) = 2.7]. Al-
thoughnumbers were small and not all oftheriskswere
significant, diseases with elevated risk included Hodg-
kin's disease (RR = 4.4), non-Hodgkin's lymphomas
(RR = 1.7), and the acute leukemias (RR = 8.8) (12).
A methodological study investigating the consistency
between parental smoking histories obtained indepen-
dently from the cancer victims and the victims' parents
was also completed; agreement was good qualitatively,
but relatively poor quantitatively (14). Links between
maternal smoking and cancer risk are being explored
further in case-control studies and will not be discussed
further here.
In part, consideration ofthe limitations ofusing tra-
ditional epidemiologic methods to investigate transpla-
cental carcinogenesis prompted consideration of alter-
native strategies that integrate laboratory and
epidemiologic studies. Rather than attempting to es-
tablish empiricaliy direct links between exposure and
disease, such biochemical or molecular approaches to
environmental epidemiologyinvestigate discrete stages
in the pathophysiological sequence of events interven-
ingbetween exposure and effect, including measures of
external exposures, internal exposures, biologically ef-
fective exposures, and biological responses (15). This
approach could be further described as the use of lab-
oratory tests todefine exposures, susceptibility factors,
disease outcomes, and the pathophysiologic sequence of
events linking exposure and disease in epidemiologic
studies of (noncardiovascular) chronic diseases.
Carcinogenesis studies in experimental animals in-
dicate that an early step in the effects ofmany chemical
carcinogens is damage to genetic material. Likewise,
most chemical agents that caused transplacental carcin-
ogenesis in experimental animals were of chemical
classes that arelikely todamage DNA. Followingthese
leads, it seemsmostappropriatetoreviewmethodsthat
have been used to detect genetic damage directly in
human fetal tissues. The specific approaches that will
be included here are summarized in Table 2. Animal
Table 2. Detection of mutagens in body fluids by bacterial
assays.
Site Genetic damage
Chromosome Aberrations, micronuclei, sister
chromatid exchanges
Gene or specific locus Lymphocytes resistant to 6-
thioguanine
Chemical DNA adducts
studies using several ofthese end points to detect fetal
damage were recently reviewed by Henderson (16).
Approaches to Measuring Exposure
to Mutagens and Genetic Damage in
the Fetus at Three Levels of
Organization of Genetic Material
Bacterial Mutagenesis Assays ofAmniotic
Fluid
Bacterial mutagenesis assays of human body fluids
provide a method for detecting levels of internal ex-
posure to mutagens. Mutagens observed may be ofen-
vironmental or endogenous origin. These assays are
conducted by obtaining specimens ofbody fluids, either
sterilizing the samples or extracting them (typically by
means ofminiature columns ofresins), andtestingthem
inbacterialmutagenesis assays. Moststudieshaveused
a protocol modified from that described by Yamasaki
and Ames (17), inwhich specimenswere extracted with
XAD-2 resins and tested with the Salmonellalmam-
malian microsomal plate assay. Further description of
the methods, results for specimens of human urines,
and the advantages and limitations ofthis approach can
be found in two reviews (18,19).
Three studies have applied bacterial mutagenesis as-
says to specimens ofhuman amniotic fluid (20-22). One
of these studies examined only specimens taken at di-
agnostic amniocenteses obtained early in the second
trimester (20). The small volume available (less than 10
mL)limitedthesensitivityoftheseassays. Whileassays
of similar volumes of urine from smokers were more
mutagenicthanurinespecimensfromnonsmokers, com-
parison ofamniotic fluid specimens from 94 nonsmokers
and 28 smokers showed no association between mater-
nal smoking and mutagenicity of amniotic fluids. Re-
gardlessofthesmokingstatusofdonors, however, spec-
imens of amniotic fluid showed small increases in
mutagenicity compared with concurrent solvent con-
trols. These increases suggest the presence of small
amounts ofmutagenic activity in many ofthe amniotic
fluid specimens not associated with maternal smoking.
A subsequent study also found no increases in mu-
tagenicityamongamnioticfluidspecimensobtaineddur-
ing the second trimester (21). However, concentrates
oflargervolumesofamnioticfluidobtainedatterm from
some of the heavy smokers studied had increased mu-
tagenic activity compared with similar specimens from
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nonsmokers (21,22). While these studies demonstrate
that exposure to mutagens in fetal tissues is occurring
in heavy smokers, they do not indicate whether expo-
sure starts onlyafter several weeks ofgestation or only
among heavy smokers. Such questions deserve further
study using more sensitive assays, such as the method
described by Kado (23) or other techniques. More sen-
sitive techniques may also help define the origin ofmu-
tagenicity not related to smoking.
Chromosomal
Three tests have been used to detect chromosomal
damage to genetic materialinthe fetus: assays forchro-
mosomal aberrations, micronuclei, and sister chromatid
exchanges in cord blood lymphocytes. Although not all
studies are consistent, the majority of studies have
found that in adults, smokers have increased frequen-
cies of chromosomal aberrations (24) and sister chro-
matid exchanges (24-26). Studies ofthe effect ofsmok-
ing on frequencies of micronuclei in lymphocytes have
given confficting results (24,25). One study reported
small increases in frequencies of SCEs induced by mi-
tomycin C among passive smokers (27).
Although karyotypes are often obtained from infants
for diagnosis of genetic diseases, few studies have in-
vestigated somaticcelldamage byanalysesofsuchspec-
imens for chromosomal aberrations. Two brief reports
foundnoevidenceofincreasedchromosomalaberrations
among cord blood lymphocytes of smokers (24,28).
These studies analyzed cord blood specimens from the
offspring of a total of 56 smokers and 42 nonsmokers.
In addition, a study of low birth weight infants found
no association between birth weight and frequencies of
chromosomal aberrations, but did not study the inde-
pendent effect of smoking (29). Smoking was also not
considered in a study that measured the frequency of
micronuclei in 28 cord blood specimens (30).
Data from four studies (31-34) evaluating the fre-
quencies of sister chromatid exchanges among women
who smoked during pregnancy and cord blood speci-
mens from their offspring are presented in Figure 1.
Each of these studies found appreciably lower rates of
sister chromatid exchanges in cord blood lymphocytes
than in maternal blood lymphocytes. In two studies
(33,34) smokingwas associated withincreased SCE val-
ues in maternal blood. Lack ofa smoking effect on ma-
ternal cells in the other studies may have been due to
the small numbers ofsubjects studied, concentration of
5-bromo-2-deoxyuridine used, the relatively low num-
bers of cigarettes smoked or relatively brief duration
ofsmokingfor most women studied (33,34). None ofthe
studies, including that by Lundgren et al. (34), which
showed aclearsmokingeffectinmaternalcellsandused
several assay conditions designed to enhance smoking
effects (Fig. 1), found a statistically significant associ-
ation between smoking and SCE frequencies in cord
blood. A total of 134 subjects were included in these
studies, with subjects about equally divided between
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FIGURE 1. Frequencies of sister chromatid exchanges in maternal
andcordblood, bysmokingstatusofthemotherduringpregnancy.
(A) Three studies using low levels of 5-bromo-2-deoxyuridine
(BUdR) in the culture media. Data are from (31-33). Frequencies
ofsisterchromatidexchangeswereconsistentlyhigherinmaternal
thaninfetal cells. Theonlysignificant difference between smokers
and nonsmokers were higher levels in maternal cells in the study
by Lundberg et al. (33). (B) A study in which SCE levels were
compared for assays done with different levels of BUdR in the
culture media and with and without a-naphthoflavone, which pre-
vious studies suggested would enhance the frequency of SCEs
among smokers. Data are from (34). Smokingwas associated with
significantly higher frequencies of SCEs only for maternal cells
using high levels (100 ,M) of BUdR in the culture media. Bars
indicate one SE.
rations, whose low frequency provides relatively little
statistical power, the aggregate statistical power ofthe
SCE studies should have been substantial. Taken to-
gether, these measurements eliminate more than a
small effect of smoking on SCEs in cord blood.
Two studies (32,35) showed no differences in SCE
frequenciesbetweenhealthynonpregnantandpregnant
women, indicating that pregnancy itselfdoes not affect
SCE values. A third study (36) did report higher SCE
and aberration rates among pregnant women in India
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(perhaps, the authors note, because offolate deficiency
during pregnancy). In other data from studies ofSCEs
incordblood, Seshadrietal. (32)reportedanassociation
between moderate or high consumption of alcohol by
the mother and high frequencies of SCEs in maternal
blood but not cord blood samples. In addition to these
studies, Hatcher and Hook (37) found no association
between the SCE frequencies in cord blood specimens
and either rates of chromosomal aberrations or birth
weight. Both their data and data ofDas et al. (38) sug-
gest rapid reductions in SCE frequencies after birth.
Neither ofthese latter two studies examined effects of
smoking on SCE frequencies.
Gene or Specific Locus Effects
Although there currently is no well-established
method for detecting genetic damage occurring in vivo
atthelevelofthegeneorspecificlocusinhumansomatic
cells, two laboratory approaches are in advanced stages
of development. One of these assays, developed by
Strauss and Albertini (39), analyzes peripheral blood
lymphocytes for resistance to 6-thioguanine. Resistant
cells have lost activity of the enzyme hypoxanthine-
guanine phosphoribosyl transferase (HGPRT), presum-
ably due to mutational loss of gene function, making
themunabletoactivatethe6-thioguaninetometabolites
that interfere with lymphocyte activation or prolifera-
tion. In the initial versions ofthis assay, resistant cells
are scored autoradiographically by their ability to take
up tritiated thymidine (39). Recent technical develop-
ments provide an alternative means for scoring: the
ability oflymphocytes to make clones (40-43). Genetic
material from clones obtained by the latter approach
can then be analyzed further, allowing demonstration
ofthe molecular basis ofchanges at the HGPRT locus.
Using this approach, in early studies, restriction-frag-
ment analysis using Southern blots showed substantial
gene alterations notvisible cytogenetically inabout 50%
of 6-thioguanine-resistant lymphocyte clones. Changes
included apparent deletions, new bands, and exon am-
plifications (44,45).
A second technique for direct measurement of puta-
tive mutations in somatic cells is the detection of gene
loss by quantitating erythrocytes that have lost expres-
sion of glycophorin-A membrane antigens. Individuals
heterozygous at the glycophorin locus should have two
glycophorin antigens on the surface of their red cells.
This assay quantitates the frequency at which red cells
from heterozygous individuals do not react with mono-
clonal antibodies against one of the antigens. Advan-
tages of the glycophorin-A assay are that it requires
fewer in vitro manipulations than the lymphocyte as-
says, it uses a more homogeneous target tissue, and it
has a more automated scoring system (46,47).
Atthistime onlythe assayfor6-thioguanine hasbeen
used to study specimens of cord blood. Albertini et al.
(48) studied specimens from 58 normal pregnancies us-
ingtheautoradiographic assay. The mean value forvar-
iantcellswas2per106cells. Logisticregressionanalysis
suggested that an elevated frequency of variant cells
was associated with use of caffeine (p < 0.03); too few
smokers were studied to allow investigation ofsmoking
effects. Henderson et al. (43) recently reported results
from nine cord blood specimens assayed usingthe clon-
ing technique. Variant frequencies were markedly
lower in these cord blood specimens than in adult blood
specimens, but the sample was too smallto allow analy-
sis of determinants of variant frequencies from either
specimen source.
Chemical Modifications of DNA (DNA
Adducts)
Chemical alteration of DNA is a fundamental mech-
anism by which environmental agents cause adverse
effects in genetic material. Techniques used to measure
chemical modifications to DNA include assays for un-
scheduled DNA synthesis, DNA strand breaks, and
chemical addition products (adducts). While each of
these approaches have been able to detect changes fol-
lowingrelativelyhighdosesofexposureinexperimental
studies, assays with sufficient sensitivity to measure in
vivo effects in human subjects have become available
only recently. The assays with the greatest sensitivity
are procedures for measuring DNA adducts.
In experimental studies, the incorporation of radio-
labeled chemicals into DNA and direct physiochemical
analysis for adducts (e.g., by use of high-performance
liquid chromatographic separation and fluorescent de-
tection of adducts) are the analytical approaches most
frequently used to measure DNA adducts. The former
approach would require administration ofhigh levels of
radioactivity, and the latter approach has not been suf-
ficiently sensitive to measure formation of adducts in
vivo in humans.
Because of limitations in the techniques commonly
used to detect DNA adducts, studies of DNA adducts
formedinvivo inhumantissuesused two otherrecently
developed methods for detecting adducts. One method,
an immunologic approach, measures adducts in DNA
fromtissuesusingradioimmunoassaysorenzyme-linked
immunosorbant assays (ELISAs) conducted with anti-
bodies against DNA adducted with known chemicals
(49-52). The second method, 32P-postlabeling (53,54),
is performed by isolating DNA, digesting it to mon-
onucleotides, and postlabeling the mononucleotide with
radioactive phosphate using an enzymatic process that
is highly specific for DNA nucleotides, including ad-
ducts. Nucleotidescontainingaromaticadductsarethen
separated from normal nucleotides by thin-layer chro-
matography, and autoradiograms are made showing
maps, or fingerprints, of DNA adducts. Levels of the
adducts can then be estimated by the density of the
autoradiograms or, more accurately, by scraping the
thin-layer chromatograms and quantitating the radio-
activity present (53,54).
32P-Postlabeling was used recently to demonstrate
DNA adducts in fetal mouse tissues after the admin-
istration ofchemical carcinogens to pregnant mice (55).
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32P-Postlabeling also demonstrated that chronic admin-
istration ofdiethylstilbestrol results in the formation of
DNA adducts in the kidney of male Syrian hamsters
(56). Adduct formation was specific for the kidney,
which is also the specific target organ for diethylstil-
bestrol carcinogenesis inthis species. Subsequent study
demonstrated thatthe adducts werearesult ofestrogen
induction of endogenous chemicals to bind to DNA
rather than adducts directly formed by estrogen (57).
To investigate whether modifications to fetal DNA
could be detected in humans by these techniques, 43
specimens of human placental tissue from smokers and
nonsmokers were analyzed bybothofthese approaches.
Methods and results ofthis study are described in more
detail elsewhere (52,58). Briefly, women were enrolled
at about the seventh month ofpregnancy, their medical
records were abstracted and questionnaires were ad-
ministered, blood specimens were obtained at the time
of enrollment into the study, and maternal blood, cord
blood, and placental specimens were gathered at the
time of parturition. In addition to demographic data,
the questionnaires obtained detailed histories ofthe use
of cigarettes and exposures to potentially toxic chemi-
cals during pregnancy. Blood specimens were analyzed
for three biochemical markers of exposure to tobacco
smoke: carboxyhemoglobin, cotinine (the major metab-
olite ofnicotine), and thiocyanate. Placental specimens
were analyzed for the presence of DNA adducts using
antibodies to DNA modified with benzo[a]pyrene dihy-
drodiol epoxide (BPDE-I) in ELISA assays and with
the adduct intensification modification (54) of the 32p-
postlabeling assay (52,58,59).
Although results ofthe ELISA assays indicated that
placental DNA contained material reacting with anti-
bodies against BPDE-I modified DNA, levels were sim-
ilar for specimens from nonsmokers and smokers (52).
The 32P-postlabeling assay detected a total of seven
chromatographically distinct adducts. The adduct ob-
served most commonly, adduct 1, was strongly associ-
ated with maternal smoking: it was observed in 22 of
24 specimens ofsmokers, but only in 3 of 19 specimens
fromnonsmokers. Levels differeddramaticallybetween
nonsmokers and smokers (Fig. 2). The othersixadducts
were found less frequently than adduct 1. Two of the
six were present onlyin nonsmokers; two other adducts
were found almost exclusively in smokers. The small
numbers ofstudy subjects madeit difficult to determine
whether the latter adducts are actually associated with
smoking (52,58). Recent unpublished data from alarger
group of study subjects allowed more quantitative
analysis of associations between adduct levels and the
intensityofexposuretosmokingasdeterminedbyques-
tionnaire and biochemical data (carboxyhemoglobin, co-
tinine, and thiocyanate levels), effects of confounding
factors on adduct levels, and associations between ad-
duct levels and birth weight [which is known to be 200
to 300 g less among the offspring of smokers (60,61)].
Estimates of intensity of exposure to tobacco smoke
from questionnaire data had much weaker associations








FIGURE 2. Mean levels of adduct 1 estimated from the 32P-postla-
beling assay, by smoking status ofthe mother during pregnancy.
Bars indicate one SE. Data are from (58).
data, so that quantitative relationships might not have
been recognized if only questionnaire data were avail-
able. Among smokers, levels of adducts were better
predictors of decreased birth weight and infant length
at birth than biochemical or questionnaire data (62).
Although many research questions can be addressed
without knowing the chemical structure ofthe adducts,
the identity ofchemicals causing the adducts and their
structureisofgreatinterest. Levelsofadductsdetected
with the very sensitive 32P-postlabeling procedure are
very low; however, the best estimate for the highest
levels of adduct 1 in placentae is about one adduct in 2
x 108 nucleotides (63). Thus, about 100 kg of placenta
would have to be processed to recover 1 ,ug of adduct,
making it difficult to isolate sufficient quantities of ad-
duct for identification by standard analytical chemical
methods. Other approaches are therefore being used to
identify adduct 1. One approach is cochromatography
of adducts found in placental specimens with adducts
from genotoxic aromatic chemicals known to be in to-
bacco smoke. These studies indicated that adduct 1 was
not formed by benzo[a]pyrene, benz[a]anthracene, di-
benz[a,h]anthracene, pyrene, chrysene, flouranthene,
benzo[g,h,i]perylene, 4-aminobiphenyl, ,-naphthylam-
ine, ortheisomericmethylorethylderivativesofaniline
(52). While similar studies with other chemicals con-
tinue, another approach is underinvestigation. This ap-
proach relies on the observation that cigarette smoke
condensate painted on mouse skin give adducts that
cochromatograph with adduct 1 under multiple chro-
matographic conditions (63). By chemically subfraction-
atingthecigarette smokecondensate andfollowingfrac-
tions containing adduct 1, it should eventually be
possible to identify this and other adducts. These two
approaches may serve as models for the identification
of chemical modifications to DNA in tissues from indi-
viduals with environmental or occupational exposures.
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Discussion
Strengths and Limitations of Studies on
the Effects of Smoking
The comprehensiveness and statistical powerofstud-
ies reviewed here vary widely. Only preliminary data
are available for several approaches to measurement of
genetic damage, including studies of chromosomal ab-
errations, micronuclei, and 6-thioguanineresistant lym-
phocytes. Investigations of the presence of mutagenic
material in amniotic fluids are more complete, and dem-
onstratedthat"heavysmokers may exposetheirunborn
children to mutagenic substances" (22). The studies us-
ing the 32P-postlabeling assay demonstrated a clear as-
sociation between cigarette smoking and in vivo for-
mation of covalent DNA adducts in humans. Even
relativelymodest useofcigarettesinducesmodifications
in genetic material in the placenta. The findings sug-
gestedthatthe majoradductsbeingformedbycigarette
smoking in vivo may not be caused by several of the
most intensely studied polycyclic aromatic hydrocar-
bons or by aromatic amines in cigarette smoke. Data
from this assay also suggested the presence of several
adducts not associated with smoking; investigation of
their origin will require analysis of additional speci-
mens. This approach may ultimately lead to the defi-
nition of chemical components of cigarette smoke and
otherenvironmental exposures that mostseverelydam-
age DNA in vivo (52,58,59,63). The approach may also
be used to investigate the extent that adducts are
formed in specific tissues. Likewise, ifcoupled with as-
says ofthe same study subjects for enzyme inducibility
orDNArepair, thisapproach maybeusefulforstudying
associations between metabolic or repair capacities of
tissues or individuals and adduct levels. (In fact, it is
possible that some of the smoking-related adducts are
aresult ofsmoking-associated inductionofenzymesthat
cause endogenous chemicals to form adducts or loss of
repair leading to persistence of adducts from other
sources.)
Assays for sister chromatid exchanges in cord blood
lymphocytes are the only example where a fairly com-
prehensive series ofstudies did not demonstrate effects
from smoking. The absence of a smoking effect on the
frequency ofSCEs in cord blood may be because oflack
oftransplacental passage of substances responsible for
this effect, heightened DNA repair processes in the
fetus, an inadequate period of exposure of the newly
arising lymphocytes in the fetus, or other causes (34).
Implications for Studies of Determinants
of Genetic Damage Other Than Smoking
The results of these investigations suggest several
principles for studies ofother assays and agents. First,
investigations of smoking demonstrate that there are
major advantages to using situations in which exposure
is relatively well defined for initial evaluations of the
usefulness ofdifferent assays forgenetic damage. Stud-
ies ofsmoking are frequently the best available model,
and, given the number ofpotential study subjects who
are exposed to tobacco smoke, the effects of smoking
will often have to be understood in order to investigate
effects ofother agents. Second, characterization ofthe
exposures by multiple questionnaire and laboratory ap-
proaches can enhance understanding gained in such
studies, as illustrated by the clearer demonstration of
a dose-response relationship between the intensity of
smoking exposure and levels of adduct 1 when this as-
sociation was sought using the biochemical data rather
than the questionnaire data. Third, while most of the
studies reviewed considered only a single assay, it
seems likely that evaluation of assays would be facili-
tated by including multiple end points such as chro-
mosomal damage and gene mutation in the same study
wheneverpossible. Finally, studiesofsmokingtypically
point to the most useful available assays for assessing
effects ofother environmental exposures and provide a
means for judging desirable qualities of assays and
prioritizing assays for further development. For ex-
ample, in addition to its great sensitivity, the 32P-post-
labeling assay has advantages of great specificity, al-
lowing it to contribute to identification of critical
components in complex mixtures and to provide leads
to unrecognized hazards. Likewise, the technique for
assaying for 6-thioguanine-resistant lymphocytes that
provides clones of mutant cells provides not only fre-
quencies of mutation, but also information to charac-
terize the molecular nature of the mutational damage.
Emphasis should be given to development of other as-
says that yield results that are highly specific as well
as quantitative.
Implications for Future Epidemiologic
Studies
The availability of highly sensitive and specific mea-
sures ofdamage to genetic material should provide ex-
citing tools for future epidemiologic studies investigat-
ingeitherprenatal orpostnatal determinants ofdisease
risk. Such assays may be both sensitive enough to in-
vestigate effects ofubiquitous low-level exposures and/
or specific enough to be used to study small numbers of
cases orclusters ofdisease. Ideally, resultsofindividual
assays would be linked with other assays to provide
convincing data on the public health risk from an ex-
posure. Table 3 presents ahypothetical example ofsuch
a study. Note that in this scenario a single assay is not
used to connect exposure and disease, but different as-
says are used to provide evidence for exposure, biolog-
ical effect, effect in target tissue, and health effects.
Each of these multiple assays provides a slightly dif-
ferent piece of the biologic puzzle, that together may
constituteacompellingcaseforacausalassociation. The
future availability of these biomarkers should provide
a means for investigating many areas that are difficult
to approach using the tools currently available to en-
vironmental epidemiologists. One can conceive this ap-
proach as providing a means to study the etiology of
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Table 3. Data available for risk assessment from a hypothetical
future molecular epidemiologic investigation.
DNA adducts are found in human tissues.
Exposures of these individuals suggest a source ofadducts.
Environmental samples produce the same adducts in animal
or in vitro models.
Specific fractions ofthe environmental samples produce high
levels ofadducts, allowing their chemical characterization.
The adducts are at positions on nucleic acids prone to causing
specific types ofmutations.
Increased frequencies of similar mutations are observed in
cells ofexposed humans.
Similar mutations are observed in activated oncogenes found
in cancers ofindividuals with high levels of the exposure
under study.
Exposed individuals whose metabolism causes high levels of
the adduct or who repair these adducts poorly are at high
risk of the tumor.
diseases including cancer, birth defects, spontaneous
abortion, or the effects of occupational exposures or
exposures to toxic wastes or dump sites.
Although in principle each of the assays needed for
the hypothetical future epidemiologic study described
in Table 3 are available, in practice there is much work
to be done before such unified studies can be under-
taken. Preliminary to such work, disciplinary and in-
stitutional barriers to progress in the evaluation and
use of biomarkers for direct measurement of genetic
damage in humans need to be overcome. Design ofthe
most effective studies usingbiomarkers may require us
to put aside, at least for a time, our disciplinary focus
and approach these problems from a broader perspec-
tive. That perspective would draw on the most appro-
priate tools forthe problem at hand fromthe disciplines
of clinical research, epidemiology, toxicology, and mo-
lecular biology. (Perhaps this could be called the per-
spective of an environmental etiologist.)
Institutional barriers are a result ofthe fact that in-
terest in and support for investigation of each of the
factors that may cause genetic damage (genetic, life-
style, dietary, occupational, pollutants, and other en-
vironmental factors) largely come from separate insti-
tutions. Likewise, the mandate forstudying each ofthe
diseases that may result from genetic damage (genetic
diseases, cancer, adverse reproductive outcomes, ag-
ing, and others) largely resides in different institutions.
This makes it difficult to achieve an overall perspective
ofthe causes ofgenetic damage and tends to fragment
efforts. Ways to coordinate efforts while using the
strengths ofthese institutions need to be identified and
encouraged.
Finally, each ofthe assays that would be used for our
hypothetical future epidemiologic study needs tobefur-
ther characterized and critically evaluated for its sen-
sitivity, specificity, and overlap with other assays. This
evaluationprocess should be doneinanorderlymanner,
starting with use of the assays in model studies de-
tecting effects ofprecisely characterized, high levels of
exposure (such as patients receiving cancer chemother-
apy or smokers). In these initial studies the study sub-
jects are toalarge extentusedtoinvestigate properties
of the assay. Understanding gathered in these model
studies can then be used to develop studies where the
assay is used to characterize determinants ofdisease in
the population studied. When the molecular approach
to epidemiology is as fully developed as are traditional
approachestoepidemiologyandtoxicology, studiessuch
asthatdescribed inTable3shouldhelpidentifyprenatal
exposures causing the greatest risk to public health.
Assays for DNA adducts described here were conducted by Kurt
and Erika Randerath and Tommie A. Avitts using support from
USPHSgrants CA32157and CA43263, ESPR-547489, andaDuPont
Occupational and Environmental Health Grant.
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